MX2019004184A - Tratamiento con lasofoxifeno del cancer de mama. - Google Patents

Tratamiento con lasofoxifeno del cancer de mama.

Info

Publication number
MX2019004184A
MX2019004184A MX2019004184A MX2019004184A MX2019004184A MX 2019004184 A MX2019004184 A MX 2019004184A MX 2019004184 A MX2019004184 A MX 2019004184A MX 2019004184 A MX2019004184 A MX 2019004184A MX 2019004184 A MX2019004184 A MX 2019004184A
Authority
MX
Mexico
Prior art keywords
breast cancer
lasofoxifene
treatment
estrogen receptor
endocrine
Prior art date
Application number
MX2019004184A
Other languages
English (en)
Inventor
Andreano Kaitlyn
Yi CHANG Ching-
P Mcdonnell Donald
L Gaillard Stephanie
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of MX2019004184A publication Critical patent/MX2019004184A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4021-aryl substituted, e.g. piretanide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)

Abstract

La descripción proporciona métodos para el tratamiento del cáncer positivo en el receptor de estrógeno (ER+) en mujeres con una cantidad efectiva de lasofoxifeno, una sal farmacéuticamente aceptable del mismo, o un profármaco del mismo. La descripción también incluye la detección de mutaciones del gen Receptor de Estrógeno 1 (ESR1) que lleva a resistencia endocrina y tratamiento de cánceres ER+ con resistencia endocrina.
MX2019004184A 2016-10-11 2017-10-10 Tratamiento con lasofoxifeno del cancer de mama. MX2019004184A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662406859P 2016-10-11 2016-10-11
US201762457759P 2017-02-10 2017-02-10
US201762502299P 2017-05-05 2017-05-05
PCT/US2017/055970 WO2018093484A1 (en) 2016-10-11 2017-10-10 Lasofoxifene treatment of er+ breast cancer

Publications (1)

Publication Number Publication Date
MX2019004184A true MX2019004184A (es) 2019-09-27

Family

ID=60186386

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004184A MX2019004184A (es) 2016-10-11 2017-10-10 Tratamiento con lasofoxifeno del cancer de mama.
MX2021013911A MX2021013911A (es) 2016-10-11 2019-04-10 Tratamiento con lasofoxifeno del cancer de mama.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013911A MX2021013911A (es) 2016-10-11 2019-04-10 Tratamiento con lasofoxifeno del cancer de mama.

Country Status (20)

Country Link
US (6) US20180098963A1 (es)
EP (2) EP3525774B1 (es)
JP (4) JP6892151B2 (es)
KR (5) KR102623130B1 (es)
CN (3) CN112933082A (es)
AU (2) AU2017360365B2 (es)
BR (1) BR112019007254A2 (es)
CA (1) CA3040266A1 (es)
DK (1) DK3525774T3 (es)
ES (1) ES2909576T3 (es)
IL (2) IL284875B (es)
MX (2) MX2019004184A (es)
NZ (1) NZ752443A (es)
PL (1) PL3525774T3 (es)
PT (1) PT3525774T (es)
RU (1) RU2019114079A (es)
SG (2) SG10201913951YA (es)
TW (2) TWI790672B (es)
WO (2) WO2018071440A1 (es)
ZA (1) ZA201902454B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
BR112019007254A2 (pt) 2016-10-11 2019-07-02 Univ Duke tratamento lasofoxifeno de câncer de mama er+
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
WO2023230222A1 (en) * 2022-05-25 2023-11-30 Sermonix Pharmaceuticals, Inc. Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitor

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
UA51676C2 (uk) 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
WO1999065498A1 (fr) 1998-06-19 1999-12-23 Senju Pharmaceutical Co., Ltd. Agents pour remedier aux effets secondaires de l'hormone corticosurrenale
YU26700A (sh) 1999-05-24 2002-06-19 Pfizer Products Inc. Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
EP1086692A3 (en) 1999-07-28 2003-07-09 Pfizer Products Inc. Estrogen agonists and antagonists for multiple indications
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
WO2001054699A1 (en) 2000-01-28 2001-08-02 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
DE10039199A1 (de) 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
ES2228932T3 (es) 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
WO2002056903A2 (en) 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
CA2479924C (en) 2002-03-28 2008-07-15 Pfizer Products Inc. Purified lasofoxifene and a method for purification of racemic lasofoxifene by recrystallization
PA8576201A1 (es) 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
US20090012052A1 (en) 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20110015134A1 (en) 2007-04-16 2011-01-20 Retsky Michael W Method of treatment for early stage cancer
CZ2007373A3 (cs) 2007-05-29 2008-12-10 Zentiva, A. S Zpusob prípravy lasofoxifenu
US20110182888A1 (en) 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
AR075153A1 (es) 2009-01-30 2011-03-16 Glaxosmithkline Llc Compuesto hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil)-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2- tiofenocarboxamida en forma cristalina, composicion farmaceitica que lo comprende, procedimiento para prepararla, su uso para preparar un medicamento util para tratar o disminuir la
EP2239570A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for determining the estrogen receptor status of breast cancer
MX348817B (es) 2009-05-27 2017-06-30 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
EP2606130B1 (en) 2010-08-16 2019-03-13 Duke University Camkk-beta as a marker in prostate cancer
US20120052508A1 (en) * 2010-08-27 2012-03-01 Rutgers, The State University Of New Jersey Genetic markers and diagnostic methods for resistance of breast cancer to hormonal therapies
WO2012125573A2 (en) 2011-03-11 2012-09-20 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
JP2014516964A (ja) 2011-05-18 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 治療用抗igf1r合剤
WO2013056178A2 (en) * 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
CA2857061A1 (en) 2011-12-16 2013-06-20 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
US20160038506A1 (en) 2012-02-14 2016-02-11 Repros Therapeutics Inc. Selective Estrogen Receptor Modulators With Short Half-Lives and Uses Thereof
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9204286B1 (en) 2013-03-15 2015-12-01 Sprint Communications Company L.P. System and method of branding and labeling a mobile device
AU2015228860A1 (en) * 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
EP3116497A2 (en) 2014-03-13 2017-01-18 F. Hoffmann-La Roche AG Therapeutic combinations with estrogen receptor modulators
EP4035664A3 (en) 2014-03-28 2022-11-30 Duke University Treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
EP3215137A1 (en) 2014-11-07 2017-09-13 Lipoxen Technologies Limited Method for treatment of primary hormone resistant endometrial and breast cancers
CA2981301A1 (en) 2015-04-14 2016-10-20 Steven C. Quay Compositions and methods of treatment of breast disorders and estrogen-related disorders
IL297369B1 (en) * 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc RAD for use in a method to treat mutant estrogen receptor positive breast cancer or mutant estrogen receptor positive ovarian cancer
US20190231743A1 (en) 2016-10-11 2019-08-01 Sermonix Pharmaceuticals, Llc Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignancies
BR112019007254A2 (pt) 2016-10-11 2019-07-02 Univ Duke tratamento lasofoxifeno de câncer de mama er+
CN115737636A (zh) 2017-01-10 2023-03-07 王巍 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
CN112261937B (zh) 2018-04-10 2023-11-14 杜克大学 乳腺癌的拉索昔芬治疗

Also Published As

Publication number Publication date
TW201817422A (zh) 2018-05-16
EP3525774A1 (en) 2019-08-21
KR20210096316A (ko) 2021-08-04
CN112353796A (zh) 2021-02-12
PT3525774T (pt) 2022-03-30
TW202313005A (zh) 2023-04-01
US11980597B2 (en) 2024-05-14
WO2018093484A1 (en) 2018-05-24
IL265938A (en) 2019-05-30
CA3040266A1 (en) 2018-05-24
US10905659B2 (en) 2021-02-02
US20180098963A1 (en) 2018-04-12
KR102531354B1 (ko) 2023-05-11
CN110099680A (zh) 2019-08-06
SG10201913951YA (en) 2020-03-30
CN110099680B (zh) 2021-02-05
US20190151286A1 (en) 2019-05-23
RU2019114079A3 (es) 2021-07-23
US10258604B2 (en) 2019-04-16
BR112019007254A2 (pt) 2019-07-02
DK3525774T3 (da) 2022-03-14
EP4035662A1 (en) 2022-08-03
AU2017360365A1 (en) 2019-05-02
KR20240007720A (ko) 2024-01-16
US20210361596A1 (en) 2021-11-25
KR102623130B1 (ko) 2024-01-10
ZA201902454B (en) 2022-09-28
RU2019114079A (ru) 2020-11-13
JP7418052B2 (ja) 2024-01-19
JP6892151B2 (ja) 2021-06-23
IL284875B (en) 2022-07-01
KR20220151017A (ko) 2022-11-11
MX2021013911A (es) 2022-01-18
JP2021073316A (ja) 2021-05-13
TWI729227B (zh) 2021-06-01
JP7247241B2 (ja) 2023-03-28
CN112933082A (zh) 2021-06-11
NZ752443A (en) 2022-11-25
TW202137980A (zh) 2021-10-16
WO2018071440A1 (en) 2018-04-19
AU2017360365B2 (en) 2022-08-04
ES2909576T3 (es) 2022-05-09
JP2023033415A (ja) 2023-03-10
US20230233490A1 (en) 2023-07-27
JP2019529581A (ja) 2019-10-17
SG11201903236SA (en) 2019-05-30
KR102285453B1 (ko) 2021-08-05
TWI790672B (zh) 2023-01-21
JP2024026527A (ja) 2024-02-28
IL284875A (en) 2021-08-31
PL3525774T3 (pl) 2022-04-25
AU2022246480A1 (en) 2022-12-08
US20190231718A1 (en) 2019-08-01
EP3525774B1 (en) 2021-12-29
KR20190092377A (ko) 2019-08-07
IL265938B (en) 2021-08-31
KR102462433B1 (ko) 2022-11-03
US20180221335A1 (en) 2018-08-09
KR20230042390A (ko) 2023-03-28

Similar Documents

Publication Publication Date Title
MX2021013911A (es) Tratamiento con lasofoxifeno del cancer de mama.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
MX2016010082A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
MX2016011698A (es) Metodos y composiciones para modular mutantes de receptor de estrogeno.
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
PH12016502354A1 (en) Pharmaceutical composition
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MY186977A (en) Tetrasubstituted alkene compounds and their use
ZA202306801B (en) Immunotherapy methods for patients whose tumors carry a high passenger gene mutation burden
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
MX2021010035A (es) Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos.
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
IL273782A (en) Compositions of cells and bacteria for the treatment of colon cancer and methods for evaluating prognosis for these patients
IL276748A (en) Methods for the detection and treatment of prostate cancer
EP3684420A4 (en) METHOD OF TREATMENT FOR TRIPLE NEGATIVE BREAST CANCER
SG11202001796SA (en) Bacteria for targeting tumors and treating cancer
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
PH12018502360A1 (en) 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
SG11202107488PA (en) Methods of treating breast cancer with tucatinib
SG11202101395XA (en) Conjugates for use in methods of treating cancer
SG11202106295WA (en) Compositions and methods for cancer therapy
SG11202007005UA (en) Use of crassocephalum rabens extract in the treatment of breast cancer